Last reviewed · How we verify

NCT05803252

Videoconferencing-based Focused Acceptance and Commitment Therapy for Parents of SHCN Children

Completed NA Last updated 5 March 2026
What this trial tests

NA trial testing Focused Acceptance and Commitment Therapy in Neurodevelopmental Disorders in 104 participants. Completed in 28 February 2026.

Timeline
15 March 2023
Primary endpoint
30 December 2025
28 February 2026

Quick facts

Lead sponsorChinese University of Hong Kong
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment104
Start date15 March 2023
Primary completion30 December 2025
Estimated completion28 February 2026
Sites5 locations across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

21 and older, any sex, with Neurodevelopmental Disorders or Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the proposed non-randomized waitlist-controlled design study is to evaluate the feasibility, acceptability, and potential effectiveness of using a Videoconferencing-based Individual Focused Acceptance and Commitment Therapy (FACT) approach to enhance the mental well-being of parents of children with special healthcare needs (SHCN) over a three-month period after the intervention has taken place.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Focused Acceptance and Commitment Therapy

Trials testing the same drug.

Other recruiting trials for Neurodevelopmental Disorders

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing